These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1532 related articles for article (PubMed ID: 17313558)

  • 1. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.
    Faucher C; Le Corroller AG; Chabannon C; Novakovitch G; Manonni P; Moatti JP; Nouyrigat P; Maraninchi D; Blaise D
    Bone Marrow Transplant; 1996 Apr; 17(4):533-6. PubMed ID: 8722350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
    Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA
    Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
    Martínez C; Sureda A; Martino R; Cancelas JA; Madoz P; García J; Brunet S
    Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma.
    Magagnoli M; Sarina B; Balzarotti M; Castagna L; Timofeeva I; Nozza A; Bertuzzi A; Siracusano L; Sinnone M; Santoro A
    Bone Marrow Transplant; 2001 Nov; 28(10):923-7. PubMed ID: 11753545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.